Patterns of response and acquired resistance to the programmed death‐1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma. Issue 6 (21st October 2019) - Zalaudek, Iris; Corneli, Paola; Vernoni, Sibil; Fedele, Dahlia; Papa, Giovanni; Conforti, Claudio; Retrosi, Chiara; Vezzoni, Roberta; Fagotti, Serena; Longone, Michela; Farinazzo, Eleonora; di Meo, Nicola; et al.